AN2 Therapeutics Shares Slip; Pipeline Update Due This Week May Be Next Driver
AN2 Therapeutics shares closed at $4.07, down 3% ahead of CEO Eric Easom’s June 4 presentation at the Jefferies Global Healthcare Conference. Principal Accounting Officer Sarah Joanne Williams sold 265 shares on May 29 for tax withholding. AN2 holds $85.3 million in cash after a recent private placement and expects multiple Phase 2 trial readouts this year. No major press releases have been issued in the past 48 hours.